

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.



Stockholm, July 29 2018

Exercise of over-allotment option and end of the stabilization period

Carnegie Investment Bank AB (publ) ("Carnegie") exercise the over-allotment option regarding 1,970,000 shares in Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company"). The stabilization period has now ended and no further stabilization transactions will be effected.

As announced in connection with the offering to acquire newly issued shares in the Company (the "Offering") and the listing of the Company's shares on Nasdaq Stockholm, Carnegie may, acting as Sole Global Coordinator, carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the market.

Stabilization transactions have been possible to undertake on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the first day of trading in the Company's shares on Nasdaq Stockholm, i.e. 29 June 2018, and with an ending no later than 30 calendar days thereafter. The Sole Global Coordinator has, however, not been obliged to undertake any stabilization and there was no assurance that stabilization would be undertaken. Undertaken stabilization has been possible to discontinue at any time without prior notice. Transactions have, in no event, been executed at levels above the price in the Offering.

The Company granted Carnegie, in its capacity as Sole Global Coordinator, an over-allotment option within the Offering which could be utilized in whole or in part for 30 days from the first day of trading in the Company's shares on Nasdaq Stockholm (the "Over-allotment option"). The Over-allotment option encompassed up to 2,166,666 additional shares, corresponding to up to 15 percent of the total number of shares in the Offering, at a price corresponding to the price in the Offering, i.e. SEK 45, to cover any over-allotment in connection with the Offering. Such shares were allocated to investors prior to the first day of trading in the Company. The shares under the Over-allotment option could then be used for stabilization purposes or to cover any over-allotment in connection with the Offering. The Sole Global Coordinator now notifies that the Over-allotment option with respect to 1,970,000 shares has been exercised. The Company will thereby be provided with additionally approximately SEK 89 million, which means that the Company has been provided in total with approximately SEK 739 million as a result of the Offering and the Over-allotment option, before issue expenses. Immediately following registration of the new shares issued pursuant to the Over-allotment option, the number of shares and votes in the Company will amount to 35,202,347. All shares in the Company that the Sole Global Coordinator has borrowed from the Principal Owners¹ with the purpose of covering the Over-allotment in the Offering will be returned within short.

The stabilization period regarding the Offering has now ended and no further stabilization transactions will be executed. Specified below is a summary of the stabilization transactions that have been executed during the stabilization period in accordance with the press release of 12 July 2018. All transactions during the stabilization period have been executed on Nasdaq Stockholm and no stabilization transactions have been executed on other dates than those specified below. The contact person at Carnegie is Magnus Andersson (tel: +468- 5886 8800).

¹ The "Principal Owners" refers to Stiftelsen Industrifonden, Investinor AS and Bengt Julander through the company Linc AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.



Stabilization transactions:	
Date	SEK (Interval)
2018-07-03	45.00 - 45.00
2018-07-04	44.90 - 45.00
2018-07-05	45.00 - 45.00
2018-07-06	44.95 - 45.00

For further information, please contact:

Renée Aguiar-Lucander, CEO at Calliditas

E-mail: renee.lucander@calliditas.com

Telephone: +46 722 52 10 06

Mikael Widell, Head of Communications at Calliditas

E-mail: mikael.widell@calliditas.com

Telephone: +46 703 11 99 60

www.calliditas.se/en/

The information in this press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at 18:30 CEST on July 29 2018.

Important information

This announcement is not and does not form a part of any offer for sale of securities.

Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, the United States or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “**Prospectus Directive**”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.